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ABSTRACT
Monitoring of HF (heart failure) with intracardiac pressure, intrathoracic impedance and/or
natriuretic peptide levels has been advocated. We aimed to investigate possible differences in
the response patterns of each of these monitoring modalities during HF decompensation that may
have an impact on the potential for early therapeutic intervention. Six sheep were implanted with
a LAP (left atrial pressure) sensor and a CRT-D (cardiac resynchronization therapy deﬁbrillator)
capable of monitoring impedance along six lead conﬁguration vectors. An estimate of ALAP (LAP
from admittance) was determined by linear regression. HF was induced by rapid ventricular pacing
at 180 and 220 bpm (beats/min) for a week each, followed by a third week with daily pacing
suspensions for increasing durations (1–5 h). Incremental pacing induced progressively severe HF
reﬂected in increases in LAP (5.9 + − 0.4 to 24.5 + − 1.6 mmHg) and plasma atrial (20 + − 3 to 197
+ − 36 pmol/l) and B-type natriuretic peptide (3.7 + − 0.7 to 32.7 + − 5.4 pmol/l) (all P<0.001) levels.
All impedance vectors decreased in proportion to HF severity (all P<0.001), with the LVring (left
ventricular)-case vector correlating best with LAP (r2 = 0.63, P<0.001). Natriuretic peptides
closely paralleled rapid acute changes in LAP during alterations in pacing (P<0.001), whereas
impedance changes were delayed relative to LAP. ALAP exhibited good agreement with LAP. In
summary, impedance measured with an LV lead correlates signiﬁcantly with changes in LAP, but
exhibits a delayed response to acute alterations. Natriuretic peptides respond rapidly to acute
LAP changes. Direct LAP, impedance and natriuretic peptide measurements all show promise as
early indicators of worsening HF. ALAP provides an estimate of LAP that may be clinically useful.
INTRODUCTION
HF (heart failure) is one of the most common causes for
hospitalization in the western world and is associated
with high morbidity, mortality and economic costs
[1]. Despite treatment advances and more intensive
clinical monitoring, rehospitalization due to acute
decompensation of HF remains high, with pulmonary
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congestion being the most common precipitant for re-
admission [2]. It has been shown that haemodynamic
deterioration may precede the development of severe
symptoms of pulmonary congestion and acute HF
hospitalization by up to 2 weeks [3,4]. Early detection
of decompensation may provide an opportunity for a
therapeutic intervention that could prevent hospitaliz-
ation and potentially improve both quality of life and
survival.Clinicalexperienceandrecentstudiesevaluating
the use of standard clinical parameters such as weight
gain or symptoms demonstrate a lack of sensitivity in
detecting decompensation and thus a limited utility for
reducing hospitalization [5]. Incorporating implantable
sensors or biomarkers into the monitoring strategy
could potentially facilitate early detection of clinical
decompensation.
LAP (left atrial pressure) is a sensitive indicator
of heart function, and elevated LAP leads directly to
pulmonary congestion and oedema. Previous studies
using surrogate estimates for LAP derived from RV
(right ventricular) indices suggest there may be a role
for such haemodynamic monitoring in HF management
[4,6]. Indeed, recent work using directly measured
LAP found that a physician-directed patient self-
management therapeutic paradigm guided by daily LAP
measurements in ambulatory HF patients was associated
with improved clinical status and fewer hospitalizations
[7]. A growing number of HF patients are receiving
implantable CRT (cardiac resynchronization therapy)
devices with or without deﬁbrillators [CRT-D (cardiac
resynchronization therapy deﬁbrillator]. In addition to
acting as pacemakers and deﬁbrillators, newer CRT-D
systems have the capability of measuring Z (intrathoracic
impedance), which can be used as an indicator of
ﬂuid volume status. With worsening HF, increasing
intracardiac and intrathoracic ﬂuid volumes results in
a fall in intrathoracic impedance. Initial attempts to
measure intrathoracic impedance using the RV lead
to detect pulmonary oedema in HF patients proved
feasible, but demonstrated suboptimal sensitivity and
speciﬁcity [4,8]. A recent study in dogs demonstrated
that intrathoracic impedance vectors derived from a LV
(left ventricular) lead are responsive to physiological
changes during HF and may provide opportunity
for improved sensitivity and speciﬁcity in detecting
increasing intracardiac and intrathoracic ﬂuid volumes
[9]. Since acute changes in LAP are associated with
changes in intracardiac and ultimately intrathoracic ﬂuid
volumes, there is potential for deriving an estimate of
LAP based on intrathoracic impedance measurements.
Plasma levels of the cardiac natriuretic peptides
[ANP and BNP (atrial and B-type natriuretic peptide),
respectively] reﬂect cardiac function and clinical status in
HF and have also been advocated for HF monitoring
[10,11]. Their role in both monitoring and guiding
therapy in HF is still the subject of some debate and of
ongoing study [12–14]. An improved understanding of
the dynamic relationship between LAP and circulating
levels of the natriuretic peptides is necessary to
fully implement serial ANP/BNP measurements in
management of HF.
Using a validated pacing-induced HF model in
sheep, we compared for the ﬁrst time the efﬁcacy
of direct LAP, intrathoracic impedance and natriuretic
peptide measurements as early indicators of worsening
cardiac function and their ability to detect acute
changes.Weinvestigatedthehypothesisthatintrathoracic
impedance signals derived from the LV lead of a CRT-D
device correlate with LAP and can indicate worsening
HF. Since natriuretic peptide levels are also known
to reﬂect changes in ﬂuid volume status [5,10,11],
we compared the response patterns in intrathoracic
impedance measurements and in natriuretic peptide
levels with acute changes in LAP. We also explored
the feasibility of estimating LAP from intrathoracic
impedance measurements.
MATERIALS AND METHODS
Ethics
The study protocol was approved by the Animal Ethics
Committee of the University of Otago, Christchurch,
New Zealand.
Implantation procedure and devices
Six sheep were implanted via the right jugular vein with
anLAPsensor(HeartPODTM ISL)andthreetransvenous
bipolar pacing leads [RA (right atrial) – TendrilTM 1688T;
RV – RiataTM 1582; LV – QuickSiteTM 1056T]. The
three pacing leads were attached to a subcutaneously
implanted CRT-D (PromoteTM RF). The implant
procedures were all performed under general anaesthesia
(thiopentone for induction; halothane/nitrous oxide
inhalation for maintenance) using ﬂuoroscopic guidance.
All implanted devices were manufactured by Cardiac
Rhythm Management Division, St Jude Medical (Sylmar,
CA, U.S.A.).
As described previously [15], the LAP sensor
was implanted into the left atrium by trans-septal
catheterization and provided direct LAP waveform
measurements, along with a corresponding far-ﬁeld
intracardiac electrocardiogram. The LAP sensor was
attached to an implantable subcutaneous antenna coil
that communicated via telemetry the LAP data to a
handheld computer [PAMTM (Patient Advisor Module)].
The data stored on the handheld PAMTM was uploaded
on to a computer for further analysis. Implantation of
the HeartPOD allowed measurement of direct LAP
throughout the study without the need for long-term
or intermittent pulmonary artery catheterization (with
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associated increased risk of infection, bleeding and other
complications).
As reported previously [9], the CRT-D is capable of
acquiring continuous measurements of intrathoracic im-
pedance along six lead conﬁguration vectors (LVring-case;
LVring–RVring;L V ring–RAring;R V ring-case;RAring-case;and
RVcoil-case) at a ﬁxed measurement interval. Stored
measurements were automatically transferred through
wireless communication to a computer for further
analysis.
A polyethylene catheter (15 guage) was inserted
percutaneously into the left jugular vein for subsequent
blood sampling.
Study protocol
Following device implantation, the sheep were rested for
a 5–10-week period, while the impedance measurements
stabilized across all vectors (stabilization period). The
sheep then underwent a week of non-pacing baseline
recordings (baseline period: study day −7 to day –1)
before initiation of 7 days of rapid RV pacing at 180
bpm (beats/min) (days 0–6) followed by 14 days at 220
bpm (days 7–20) to induce progressively severe HF
[16]. During the third week of pacing (days 14–18),
pacing at 220 bpm was suspended each day for increasing
lengths of time – starting from 1 h on the ﬁrst day and
increasing sequentially to 5 h on the ﬁfth day. Pacing was
permanently discontinued on day 21, and the sheep were
monitored for an additional 12 days (recovery period:
days 21–32).
Data acquisition and processing
Intrathoracic impedance data were automatically collec-
ted at hourly intervals throughout the study. Impedance
vectors were accepted for further analysis if there was
an absence of a lead disturbance artifact, which was
detected when there was a signiﬁcant instability in
the impedance measurements (>80  ) between those
obtainedattheonsetoftheprotocol(baselineperiod)and
those obtained following the recovery period (beyond
day 32). Admittance was calculated as the reciprocal
of the measured intrathoracic impedance (admittance =
1/Z). The relationship between admittance and LAP was
evaluated using linear regression for each of the vectors.
The equation describing the line of best ﬁt between
admittance and LAP was utilized to derive estimates of
LAP from admittance (ALAP). The relationship between
admittance and LAP was compared with the relationship
between natriuretic peptide levels and LAP.
LAP measurements were recorded in triplicate daily
throughout the study protocol and more frequently
(hourly for 6–10 h) on those days when the pacing
rate was altered. LAP was calculated by subtracting an
atmospheric reference pressure measured by an external
sensor located in the handheld PAMTM from the absolute
pressure measured directly from the sensor implanted
inside the left atrium.
Venous blood samples were drawn throughout the
study protocol (immediately after LAP measurements)
into EDTA-treated tubes on ice, centrifuged at 4◦Ca n d
stored at −80◦C before assay for plasma ANP and BNP
as described previously [16].
Statistics
LAP, natriuretic peptide and admittance results are
expressed as means + − S.E.M. Effect of pacing on these
variables was assessed using one-way repeated measures
ANOVA. Where signiﬁcant differences were identiﬁed
by ANOVA, the level of signiﬁcance between baseline
andtheindividualtimepointswasdeterminedbyFisher’s
protected least-signiﬁcant difference tests. General linear
models (regression) were used to determine the strength
of the relationship between LAP and (i) admittance
derived from two representative intrathoracic impedance
vectors (LVring-case and RVcoil-case), (ii) ANP and (iii)
BNP. The models evaluated the relationships during
periods of time when LAP was changing gradually over
an extended term as well as rapidly over a short term.
The long-term analysis was performed using all of the
data from the entire study protocol, while the short-term
analysisusedthedatafromthethirdweekofpacingwhen
therewereacutechangesinLAPaspacingwassuspended
for increasing durations of time. A value of P<0.05
was considered statistically signiﬁcant. P values were
corrected for multiple comparisons when appropriate.
Bland–Altman plots were used to analyse the agreement
of direct LAP measurements and ALAP estimated from
admittance.
RESULTS
Pacing-induced HF model
Incremental pacing induced progressively severe HF as
indicated by rises in LAP from a prepacing baseline of
5.9 + − 0.4 to 15.3 + − 1.0 mmHg following a week of pacing
at 180 bpm (P<0.001) and to 24.5 + − 1.6 mmHg after a
second week pacing at 220 bpm (P<0.001) (Figure 1).
LAP levels did not increase further during the third
week when pacing at 220 bpm was suspended daily
for 1–5 h. Figure 2 shows representative LAP waveform
data from one sheep with corresponding electrograms
during the various periods of the study protocol. Part
of the mechanism for producing an elevation in LAP
during rapid ventricular pacing appears to be cannon A-
waves that represent a simultaneous atrial and ventricular
contraction. An acute change in LAP from 24.7 to
14.5 mmHg following cessation of pacing during the
third week of pacing (days 14–18) with the disappearance
of cannon A-waves occurring within 3 min of pacing
discontinuation is shown (Figures 2C and 2D). The
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Figure 1 LAP, natriuretic peptide and LVring-case and RVcoil-case admittance vector responses in six sheep during acute
and chronic changes in pacing
Values shown are means + − S.E.M.
permanent termination of pacing (day 21) resulted in the
gradual reduction of LAP to pre-pacing baseline levels
over the subsequent 4 days (Figure 1).
Intrathoracic impedance vectors
Impedance measured across all six lead conﬁguration
vectors tended to decrease with the onset and increasing
severity of HF and then return towards baseline values
on cessation of pacing. Sample raw data from one sheep
are shown in Figure 3.
Linear regression analysis between admittance and
LAP across all sheep for the entire study duration
demonstrated that vectors that utilized the LVring
electrode (LVring-case, r2 = 0.63; LVring–RVring, r2 = 0.52
andLVring–RAring,r2 =0.50)hadthestrongestcorrelation
with LAP, vectors that utilized the RV electrodes (RVring-
case, r2 = 0.50 and RVcoil-case, r2 = 0.50) had a somewhat
reduced correlation, and vectors that utilized the
RAring electrode (RAring-case, r2 =0.33) had the weakest
correlation. The LVring-case vector and the RVcoil-case
vectorwereselectedtorepresentintrathoracicimpedance
for further analysis. Results for the LVring-case vector
are available for n = 5 (data from one sheep excluded
due to late instability in impedance measurements),
while results for RVcoil-case are available for all six
sheep.
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Figure 2 Sample data from one sheep showing LAP waveforms and intracardiac electrogram during the various phases of
the pacing protocol
Figure 3 Sample data from one sheep showing intrathoracic impedance trends for the six vectors in response to sequential
right ventricular pacing
Long-term trend analysis
Figure 1 shows the trends in LAP, admittance and
natriuretic peptide levels over the entire study protocol
averaged over all sheep. Rises in LAP in response
to incremental pacing were mirrored by LVring-case
admittance, which rose signiﬁcantly from a pre-pacing
baseline of 2.8 + − 0.19 (1000/ ) to 3.22 + − 0.17 (1000/ )
(15.0%;P<0.001)following1 weekofpacingat180bpm
and to 3.54 + − 0.17 (1000/ ) (26.4%; P<0.001) after
a further week of pacing at 220 bpm. The RVcoil-case
admittance also changed signiﬁcantly across all pacing
periods, increasing from a baseline of 15.97 + − 0.42
(1000/ ) to 17.41 + − 0.60 (1000/ ) (9.0%, 180 bpm;
P<0.05) and to 19.18 + − 0.64 (1000/ ) (20.1%, 220 bpm;
P<0.001). Similar to LAP, admittance levels for both
the LVring-case and the RVcoil-case vectors were sustained
during the third week of pacing. On permanent cessation
of pacing, both LVring-case and RVcoil-case admittance
returned to pre-pacing baseline levels by 1 week (day 28),
aresponsealsosimilarto,butsomewhatslowerthan,that
of LAP.
A comparable overall trend was observed for plasma
natriuretic peptide levels over the course of the study as
LAP varied following alterations in pacing (Figure 1).
In response to progressively increasing LAP, there were
approx. 10-fold elevations in plasma natriuretic peptide
levels, with BNP increasing from a prepacing baseline
concentration of 3.7 + − 0.7 pmol/l (13.2 + − 2 pg/ml) to
18.4 + − 2.4 pmol/l (64 + − 8 pg/ml) (180 bpm; P<0.001)
after 1 week and to 32.7 + − 5.4 pmol/l (113 + − 19 pg/ml)
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Table 1 Summary of the general linear model results
correlating LAP with plasma ANP and BNP, and LV and RV
admittance vectors
NS, not signiﬁcant.
Long-term analysis Short-term analysis
Parameter Entire protocol Third week of pacing
Plasma ANP P =0.003 P <0.001
Plasma BNP NS (P =0.084) P <0.001
LVring-case admittance P <0.001 P <0.001
RVcoil-case admittance P <0.001 NS
(220 bpm; P<0.001) following 2 weeks of pacing.
Similarly, ANP rose from a baseline of 20 + − 3 to 142 + −
17 pmol/l (180 bpm; P<0.001) and to 197 + − 36 pmol/l
(220 bpm; P<0.001). During the third week of pacing,
natriuretic peptide levels were also maintained. The
permanent termination of pacing (day 21) resulted in
a rapid decline in plasma ANP and BNP to baseline
levels within 2 days, a shorter duration compared with
LAP. The trend data also demonstrated the presence
of an ‘overshoot’ in ANP and BNP levels upon the
initiation of rapid pacing (day 0) and upon increasing the
pacing rate to 220 bpm (day 7). The latter overshoot for
ANP was apparent for less than a day, while for BNP, it
extended to 3 days before declining.
Analysesacrosstheentirestudyprotocolusingalltime
points revealed that LAP correlated signiﬁcantly with
LVring-case admittance, RVcoil-case admittance and ANP
(Table 1). A similar trend was evident for BNP (Table 1),
but it is likely that the differences in responses during the
ﬁrst220-bpmpacingweekbetweenLAP(steadyrise)and
BNP (3-day overshoot and decline) negatively affected
the relationship.
Short-term trend analysis
During the third week of pacing (days 14–18), acute
interruptions in pacing for increasing durations of
time (1–5 h sequentially over the 5 days) induced rapid
falls (within an hour) in LAP averaging 9.1 + − 0.1
mmHg (P<0.001) (Figure 4). Recommencement of
pacing on each day restored LAP promptly to levels
observed prior to pacing termination. Changes in plasma
natriuretic peptide concentrations over this 5-day period
largely paralleled those of LAP, with ANP and BNP
falling on average by 137 + − 8 and 20.9 + − 1.5 pmol/l,
respectively (both P<0.001), following disruption of
pacing.However,pacingresumptionresultedinastriking
peak and ‘overshoot’ in the ﬁrst hour followed by a re-
establishment of ANP and BNP at levels observed prior
to pacing cessation.
LVring-caseadmittancealsoshowedsigniﬁcantchanges
across this week (P<0.001), decreasing with pacing
suspension and rising on pacing resumption (Figure 4).
However, the rate and relative magnitude of changes in
admittance were markedly less than those observed for
LAP, ANP and BNP. In contrast, RVcoil-case admittance
showed no signiﬁcant changes (falls or rises) across this
off/on pacing week (Figure 4).
Analyses limited to the third week of pacing showed
that LAP correlated well with LVring-case admittance,
BNP and ANP, but not with RVcoil-case admittance
(Table 1).
Estimated ALAP
Figure 5 shows the relationship between admittance
and LAP for the LVring-case and RVcoil-case impedance
vectors. For both vectors, the relationship of admittance
to LAP displays a hysteresis (retardation of response)
both as LAP rises and falls. Of note, data recorded while
pacing is on generally falls to the left of (above) the line
of best ﬁt, whereas data recorded when pacing is off falls
to the right of (below) the line of best ﬁt. Despite the
hysteresis and clear separation of data from the ‘pacing-
on’phasesrelativeto‘pacing-off’phases,linearregression
still resulted in a positive correlation of admittance to
LAP with r2 values of 0.63 and 0.50 for LVring-case and
RVcoil-case vectors, respectively.
To assess the degree to which a simple linear model
may be used to derive estimates of LAP from admittance,
the equations describing the line of best ﬁt were then
used to calculate ALAP (Figure 5). Bland–Altman plots
(Figure 6) were used to assess the agreement between
LAP and ALAP.F o rL V ring-case and RVcoil-case vectors,
2 S.D. of the error between ALAP a n dL A Pe q u a t e dt o
8.3 and 9.6 mmHg, respectively. Results for other vectors
(results not shown) were as follows: LVring-RAring = 8.7
mmHg, LVring–RVring = 9.2 mmHg, RAring-case = 10.3
mmHg and RVring-case = 9.9 mmHg.
DISCUSSION
Reducing the burden of HF hospitalizations remains
a critical problem for chronic HF patients and the
physicians who manage them. Improved strategies for
haemodynamic and ﬂuid volume monitoring, combined
with earlier intervention in response to increasing ﬁlling
pressures and ﬂuid volumes, are needed to avoid and to
interrupt the development of acute decompensation in
chronic HF. The present study examined the relationship
between intrathoracic impedance signals derived from a
CRT-D device and direct LAP measurements acquired
with a permanently implantable LAP monitor over
acute and chronic alterations in HF severity. The study
also compared the response patterns in intrathoracic
impedance and in natriuretic peptide levels with changes
in LAP. We found that LAP increased over several weeks
intotherangeexpectedtoproducepulmonarycongestion
in response to rapid ventricular pacing [16]. Changes in
ANP and BNP concentrations, as well as the rapidity of
the response, generally mirrored those of LAP across all
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Figure 4 Expanded view of LAP, natriuretic peptide and LVring-case and RVcoil-case admittance vector responses in six
sheep during acute on/off changes in pacing
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phases of the study. All six impedance vectors decreased
in response to rapid ventricular pacing, with vectors
utilizing the LV lead exhibiting the best correlation
with LAP (r2 = 0.63) and vectors utilizing the RV lead
demonstratingasomewhatreducedcorrelationwithLAP
(r2 = 0.50). This is the ﬁrst study to assess the feasibility
of estimating LAP from intrathoracic admittance (ALAP),
with results demonstrating a close relationship between
the two variables (LAP and ALAP).
Intrathoracic impedance
The long-term trends seen in the present study with
intrathoracic impedance decreasing in response to rapid
ventricular pacing are consistent with earlier studies
[4,8,9]. Similar to our ﬁndings, prior work in a canine
model of pacing-induced HF [9], where HF progression
was monitored with either an LAP pressure sensor
or LVEDV (LV end-diastolic volume) measurements
via echocardiography, demonstrated that intrathoracic
impedance using the LVring-case vector had the fastest
and largest change in response to HF severity and
increasingLAP.Thisearlierstudyadditionallyfoundthat
LVring-case impedance measurements had a statistically
signiﬁcant inverse correlation with LVEDV, while
impedance using the RVring-case and RVcoil-case vectors
did not correlate with LVEDV. These results indicate that
LVring-caseimpedancemeasurementsmayreﬂectnotonly
LAP, but also LVEDV.
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Figure 5 Linear regression of HeartPODTM ISL LAP
recordings compared with PromoteTM RF CRT-D admittance
for (A) the LVring-case and (B) RVcoil-case impedance
vectors
Data points are from across the experimental phases of the study as follows: ,
baseline (no pacing); , pacing (180 bpm); , pacing (220 bpm); ×, pacing
off (1–5 h) during on/off week;  , recovery (no pacing). Estimated LAP from
impedance (ALAP) is calculated from the admittance using the slope and intercept
of the linear regression equation.
The present study expands on the prior work by also
examining the short-term trends seen in intrathoracic
impedance in response to acute changes in LAP and
by comparing the response pattern to that seen with
the natriuretic peptides. We found that the LVring-case
impedance vector also had the best correlation with LAP
overshort-termdurationswhenabruptchangesinpacing
werebeingperformed,butunlikethenatriureticpeptides,
there was a delay (several hours to 1 day) in the response
resulting in a hysteresis-type pattern on the correlation
plots, as well as a blunting of the response relative to
ANPandBNP.Incontrast,theRVcoil-casevectorshowed
no immediate change within a period of 1–5 h to acute
changes of LAP, but did ultimately return to baseline
over a longer time interval once pacing was terminated
permanently.
Figure 6 Bland–Altman plots for estimated ALAP compared
with LAP measured directly by the HeartPODTM ISL for (A)
LVring-case and (B) RVcoil-case vectors
LVring-case, 402 data points from ﬁve individual sheep; and RVcoil-case, 485
data points from six individual sheep each shown by different symbols. Broken
lines show the + − 2 S.D. of the difference between the two methods which were
8.3 mmHg for LVring-case and 9.6 mmHg for RVcoil-case vectors.
Mechanistic hypothesis for hysteresis
The hysteresis seen between admittance (1/Z)a n dL A P
may be a consequence of admittance reﬂecting a volume
measurement rather than a direct pressure measurement.
Changes in ﬂuid volume distribution occur more
gradually relative to changes in intracardiac pressure,
which may rapidly develop with acute alterations in
venous capacitance (preload), vascular tone (afterload),
contractility, valvular function and/or rhythm. In the
present physiological study, it was noted that part
of the mechanism for producing acute changes in
LAP was the occurrence and disappearance of cannon
A-waves with the initiation and termination of rapid
ventricular pacing. When rapid pacing was sustained,
LAP continued to climb with intracardiac ﬂuid volume,
and ultimately ﬂuid volumes within the intrathoracic
space were gradually increasing, which resulted in a
strong correlation with LAP over a long-term time
interval. When rapid ventricular pacing was abruptly
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stopped,therewasanimmediatedisappearanceofcannon
A-waves,butintracardiacandintrathoracicﬂuidvolumes
didnotinstantlydecrease,butinstead,graduallydeclined
with a lag relative to LAP. The present study suggests
that the admittance measurements derived from the
implanted CRT-D device more likely reﬂect intracardiac
and intrathoracic ﬂuid volumes rather than LAP. The
proposed mechanistic hypothesis is further supported
by an earlier study performed using a canine model of
pacing-induced HF where LVEDV exhibited a delayed
response to rapid RV pacing in comparison with the
response seen in pulmonary capillary wedge pressure
[17].
The hysteresis described in the present ovine study
is similar to the pattern expected to occur in patients
with functional MR (mitral valve regurgitation) [18].
In these patients, an acute change in afterload and/or
papillary muscle perfusion may produce an acute episode
of MR, which will result in an immediate increase in LAP
followedbyagradualanddelayedincreaseinintracardiac
andintrathoracicﬂuidvolumesiftheMRpersists.Having
the ability to detect an immediate increase in LAP with
an implantable LAP sensor offers an advantage for earlier
intervention in comparison with a CRT-D device that
has the potential to detect via admittance measurements
a subsequent rise in intracardiac and intrathoracic ﬂuid
volumes.
LAP estimation
Despite the presence of a hysteresis-type pattern on
the correlation plots between admittance and LAP, the
present study also demonstrates that a relatively accurate
estimate of LAP may be derived from intrathoracic
impedance (ALAP) with use of a linear model. Bland–
Altman plots of the difference between ALAP and direct
LAP measurements shows that, for all six vectors, there
was a relatively good agreement between LAP values
measured by the two methods. Bland–Altman analysis
determined that 95% conﬁdence limits for the mean
difference between the two methods (2 S.D.) for all six
vectors were in the range of 8.3–10.3 mmHg, which,
of note, is in a similar range for the accuracy reported
for other implantable haemodynamic monitors [19,20].
Hence, ALAP, even when using a linear model, provides
a good estimate of LAP that may be clinically useful in
providing an early warning of HF deterioration.
Limitations
As seen in the present study, one limitation of the
intrathoracic impedance measurements derived from a
CRT-D device is that a variable amount of time is
required for the impedance signals to stabilize during the
systemmaturationperiodafterimplantation.Inaddition,
shifts in intrathoracic impedance measurements may
also transpire in response to changes occurring at the
electrode/tissue interface and/or as a consequence of a
mechanical failure of the implanted lead. Intrathoracic
impedance measurements are also prone to change as a
result of non-cardiac events, such as pneumonia, pleural
effusion, pneumothorax and device pocket infection.
Impedance measurements potentially may become more
reliable when a longer period of time is allocated
for system maturation and when utilizing vectors that
employ the LVring electrode.
Natriuretic peptides
In agreement with previous work using our ovine pacing
model of HF [16], the present study demonstrates that
plasma concentrations of both ANP and BNP correlate
well overall with changes in pacing rate and LAP. Our
current data additionally shows an especially strong
relationship during the third week of the study when
acute alterations in pacing were conducted. During this
period, hormone levels fell and rose within the ﬁrst hour
ofpacingadjustment(Figure4),tightlyreﬂectingchanges
in LAP. This suggests that the natriuretic peptides may
be excellent markers of acute changes in LAP as may be
seen with acute decompensation to raised pressures or
following rapid unloading of ﬁlling pressures that would
be seen with aggressive diuretic therapy.
Although both ANP and BNP are known to reﬂect
the degree of atrial and ventricular wall stress [11],
they both also serve as a compensatory hormonal
mechanism during HF and, as demonstrated in the
presentstudy,mayhaveanaturaltendencyto‘overshoot’
in response to acute changes in LAP and haemodynamics
when rapid ventricular pacing was abruptly changed.
Although the reasons for the observed overshoot are
unclear, it may reﬂect the rapid release of both ANP
and BNP from storage in atrial granules, resulting in
some depletion of stored peptide, followed by a new
steady state of production/release in response to changed
haemodynamic stimuli over subsequent hours. ANP
correlated with LAP across all time points of the study
andhadafasterresponsewithashorter-livedovershootin
response to acute changes in pacing in comparison with
BNP. Nonetheless, BNP and the N-terminal pro-BNP,
in particular, have been advocated for HF monitoring
(by virtue of their predominantly ventricular origin and
slower clearance rate from plasma), with their potential
utility for guiding therapy ﬁrst reported a decade ago
[10].Our ﬁndings indicate that changes in bothANP and
BNP appear to be excellent markers of concordant shifts
inLAP,particularlyunderpathophysiologicalconditions
characterized by chronic volume and cardiac overload,
and also have an ability to respond rapidly to acute (over
hours) rises and falls in LAP.
In contrast with the strong relationship between
ANP/BNP and LAP demonstrated in the present study,
correlations between ﬁlling pressures and plasma BNP
levels observed in the ICU (intensive care unit) setting
have been modest at best [21]. There are a number of
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differences between our study and those set in the ICU,
where investigations performed in the latter have been
largely cross-sectional, and observations made at one
or two time points in small- to moderate-size cohorts
of subjects with advanced cardiac dysfunction. Subjects
in these studies generally exhibited ﬁlling pressures
that were either high normal or elevated, and few or
no subjects had normal or low ﬁlling pressures. In
the experimental model described in the current study,
however, multiple time points were examined under a
variety of conditions associated with ﬁlling pressures
across a wide range from normal to severely elevated.
In addition, in this model, there was no confounding
from other factors such as diuretic or vasodilator therapy
to complicate the relationship between the natriuretic
peptides and LAP.
Conclusions
In conclusion, the present study assessed head-to-
head comparisons of direct LAP measurements with
multivector intrathoracic impedance and plasma natri-
uretic peptide levels. All three strategies generally track
onset and recovery from HF. LAP has the required
accuracy and response pattern to acute physiological
changes that make it a suitable parameter for dynamically
adjusting daily prescriptions in ambulatory HF patients
based on a physician-directed patient self-management
therapeutic paradigm. Intrathoracic impedance may
be utilized to derive estimates of LAP and to
detect trends that may be indicative of a change in
clinical status. However, because of the inability of
intrathoracic impedance measurements to acutely track
rapid physiological changes and limited speciﬁcity, ALAP
may not be an optimal parameter for dynamically
adjustingdailyprescriptions.Natriureticpeptidesclosely
track acute alterations in LAP and may be utilized
for guiding HF therapy, but because the current assay
technology requires a visit to the clinic, natriuretic
peptides cannot be used for altering daily prescriptions
using a physician-directed patient self-management
therapeutic paradigm. All three strategies show promise
for improved monitoring of HF and early detection of
decompensation, either alone or in combination.
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